Abstract 2335P
Background
In invasive lung adenocarcinoma (LUAD), patients with micropapillary (MIP) or solid (SOL) components had a significantly poorer prognosis than those with only lepidic (LEP), acinar (ACI) or papillary (PAP) components. It is interesting to explore the genetic features of different histologic subtypes especially the highly aggressive components.
Methods
This study comprised four cohorts of patients who underwent complete surgical resection for lung adenocarcinoma (LUAD) and had their medical records reviewed. Cohort 1 depicted the distribution of different histological subtypes across tumor size groups. Logistic regression analysis in cohort 2 investigated the associations between driver mutations and histological subtypes. Cohort 3 utilized spatial whole-exome sequencing with laser-capture microdissection to identify genetic heterogeneity among histological components within the same tumor. Cohort 4, in conjunction with the cBioportal cohort, was employed to validate the findings obtained from cohort 3.
Results
Based on a cohort of 5,933 patients (cohort 1), this study observed varying prevalence of micropapillary (MIP) and solid (SOL) components in different tumor size groups. Furthermore, cohort 2 revealed that patients with ALK fusion or TP53 mutations had a higher probability of developing MIP/SOL components in cohort 2. To account for individual differences, tspatial whole-exome sequencing was performed using laser-capture microdissection on five patients with coexistent components, enabling the identification of genetic features within the same tumor. In tracing the evolution of components, we found that titin mutation might serve as a crucial intratumor potential driver for MIP/SOL components, which was validated by the cohort 4 of 146 LUAD patients undergoing bulk WES. Functional analysis demonstrated that TTN mutations were enriched the complement and coagulation cascades, which correlated with the pathway of cell adhesion, migration, and proliferation.
Conclusions
Collectively, the histologic subtypes of invasive LUAD were genetically different, and certain trunk genotypes might synergize with branching TTN mutation to develop highly aggressive components.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16